05.01.2023 14:33:27
|
Zai Lab And Novocure Announce LUNAR Study Meets Primary Endpoint
(RTTNews) - Zai Lab Limited (ZLAB) and Novocure (NVCR) announced the LUNAR study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in overall survival over standard therapies alone. The LUNAR study is a randomized study evaluating the safety and efficacy of Tumor Treating Fields together with standard therapies for stage 4 non-small cell lung cancer following progression.
Tumor Treating Fields or TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms.
Novocure plans to file a Premarket Approval application with the FDA in the second half of 2023. Novocure also plans to file for a CE Mark in the European Union concurrently with the FDA submission.
For More Such Health News, visit rttnews.com.
Shares of Novocure are up 68% in pre-market trade on Thursday.
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Zai Lab Ltd Unsponsored American Deposit Receipt Repr 1 Shmehr Nachrichten
12.02.25 |
Erste Schätzungen: Zai Lab legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net) | |
11.11.24 |
Ausblick: Zai Lab verkündet Quartalsergebnis zum jüngsten Jahresviertel (finanzen.net) | |
28.10.24 |
Erste Schätzungen: Zai Lab mit Zahlen zum abgelaufenen Quartal (finanzen.net) |
Analysen zu Zai Lab Ltd Unsponsored American Deposit Receipt Repr 1 Shmehr Analysen
Aktien in diesem Artikel
NovoCure Limited | 20,74 | 1,12% |
|
Zai Lab Ltd Unsponsored American Deposit Receipt Repr 1 Sh | 27,60 | 3,76% |
|